Author

Lana Andrianova

Observed name: L. Andrianova

Institution: Exelixis (United States)

Observed institution: Exelixis (United States)

OpenAlex ID: A5000959268

A phase 1b multitumor cohort study of cabozantinib plus atezolizumab in advanced solid tumors (COSMIC-021): Results of the colorectal cancer cohort.

2022 · Thomas Adam Abrams, Syed Mohammad Ali Kazmi, et al. · Journal of Clinical Oncology · 20

Cabozantinib (C) in combination with atezolizumab (A) in urothelial carcinoma (UC): Results from Cohorts 3, 4, 5 of the COSMIC-021 study.

2022 · Sumanta K. Pal, Neeraj Agarwal, et al. · Journal of Clinical Oncology · 8

A phase 1 dose-escalation and expansion-cohort study of the oral CDK7 inhibitor XL102 as a single-agent and in combination therapy in patients (pts) with advanced solid tumors.

2022 · Geoffrey Shapiro, Minal A. Barve, et al. · Journal of Clinical Oncology · 7

Cabozantinib in combination with atezolizumab in non-clear cell renal cell carcinoma: Extended follow-up results of cohort 10 of the COSMIC-021 study.

2023 · Bradley Alexander McGregor, Neeraj Agarwal, et al. · Journal of Clinical Oncology · 5

2594MO Association of circulating kidney injury molecule-1 (KIM-1) levels with clinical outcomes in advanced renal cell carcinoma (aRCC): Retrospective analysis of COSMIC-313

2025 · W. Xu, T.K. Choueiri, et al. · Annals of Oncology · 4

EP08.02-081 Cabozantinib Plus Atezolizumab in First or Second-Line Advanced NSCLC and Previously-Treated EGFR Mutant Advanced NSCLC

2022 · J.W. Neal, F.L. Lim, et al. · Journal of Thoracic Oncology · 2

Cabozantinib plus nivolumab (C+N) versus sunitinib (S) in patients with advanced renal cell carcinoma (aRCC) and bone metastasis: Updated subgroup analysis of the phase 3 CheckMate-9ER trial.

2026 · Andrea B. Apolo, Bernard Escudier, et al. · Journal of Clinical Oncology · 1

Zanzalintinib (zanza) + nivolumab (nivo) ± relatlimab (rela) in patients (pts) with advanced solid tumors: Results from two dose-escalation cohorts of the phase 1b STELLAR 002 study.

2025 · Benjamin Garmezy, Bert O'Neil, et al. · Journal of Clinical Oncology · 1

Zanzalintinib (zanza) + nivolumab (nivo) ± relatlimab (rela) in patients (pts) with previously untreated clear cell renal cell carcinoma (ccRCC): Results from an expansion cohort of the phase 1b STELLAR-002 study.

2025 · Jad Chahoud, Bradley Alexander McGregor, et al. · Journal of Clinical Oncology · 1

531 A Phase 1b multi-tumor cohort study of cabozantinib plus atezolizumab in advanced solid tumors: results of the triple-negative breast cancer, ovarian cancer, and endometrial cancer cohorts

2021 · Ira Winer, Akhila Wimalasingham, et al. · Regular and Young Investigator Award Abstracts · 1

Cabozantinib plus nivolumab (C+N) versus sunitinib (S) in patients with advanced renal cell carcinoma (aRCC) and liver metastasis: Subgroup analysis of the phase 3 CheckMate-9ER trial.

2026 · Amishi Yogesh Shah, Bernard Escudier, et al. · Journal of Clinical Oncology

Characterization of depth and durability of response in patients (pts) with previously untreated advanced renal cell carcinoma (aRCC) who received cabozantinib plus nivolumab (C+N): Long-term follow-up and exploratory analysis of CheckMate 9ER.

2026 · Cristina Suárez, Robert J. Motzer, et al. · Journal of Clinical Oncology

Works count: 12

Citation count: 50

H-index: 4

I10-index: 1